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Despite advances in preventive treatments for HIV, children continue to become infected 
with HIV. Research has investigated adult and adolescents’ willingness to participate 
in hypothetical HIV vaccine trials; however, maternal willingness to enroll their infants 
in such trials remains underexplored. aim: This study explored the factors influencing 
mothers’ decision-making about enrolling their HIV negative infants in a hypothetical HIV 
vaccine trial. Methods: HIV infected and uninfected mothers (n = 22) were interviewed. 
Results: Several factors were identified as influencing the mothers’ decisions, including 
perceptions and knowledge of HIV and vaccines. conclusion: Maternal concerns about 
protecting their infants from HIV were also identified and mothers indicated that they were 
eager to vaccinate their children. Insufficient information and reassurance regarding vaccine 
trial safety and efficacy influenced maternal reluctance to enroll their child.
First draft submitted: 2 September 2016; Accepted for publication: 31 October 2016; 
Published online: 21 December 2016
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Despite the success of existing prevention strategies such as prevention of mother-to-child transmis-
sion programs, exclusive breastfeeding and antiretroviral therapy (ART), new HIV infections in 
infants and young children persist. In South Africa, an estimated 360,000 children aged 0–14 years 
were living with HIV in 2013, representing close to 7% (16,000) of new infections globally among 
children in that age range during that year [1]. However, while the aforementioned strategies offer 
protection of HIV during infancy, HIV-exposed newborns who are not infected at birth or during 
breastfeeding remain at risk of HIV infection during adolescence and adulthood [2]. One approach 
to reduce HIV incidence is an effective and safe HIV vaccine.
The development of a safe, tolerable and effective vaccine for infants is lagging far behind those 
of adults [3]. In terms of adult vaccines, only one Phase III trial to date (RV144) has demonstrated 
modest efficacy [4]. Compared with adolescents and adults, infants stand to benefit the most from 
an HIV vaccine [Rosenthal KL, Unpublished data]. Preventative vaccinations would not only provide 
infants with life-long protection against HIV, but also allow HIV-positive mothers to breastfeed 
their infants without the risk of vertical transmission. Large numbers (thousands for Phase III 
trials) of infants will be needed to participate in HIV vaccine trials [5,6]. While the literature offers 
some insight into adolescents and adults’ willingness to participate in HIV vaccine trials [7–10], 
less is known about the willingness of parents to enroll their infants and children in HIV vaccine 
trials and the factors that influence such a decision.
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In a study of hypothetical HIV vaccine trial 
acceptability, nearly all women reported (97%) 
that they would vaccinate their child once 
against HIV if this were an option [11]. This total 
decreased to 80% willing to vaccinate if vaccina-
tion was required every 3 months. Further, only 
64% (513 out of 805) agreed to participate in a 
vaccine trial. Reasons for not wanting to partici-
pate included concerns about the side effects of 
the vaccine, partner objection, fear of discrimi-
nation by family and others and fear of contact-
ing HIV through participation. These barriers 
to participation are similar to those found in the 
adult and adolescent literature [3,12–17]. However, 
as this study was based in Kenya, it is unclear 
whether similar results would be seen in other 
contexts.
Understanding the factors that influence pedi-
atric trial participation is essential if large-scale 
trials are to proceed ethically and in a methodo-
logically sound manner. Unlike adults, infants 
are unable to provide consent to participation in 
these trials. In this study, we expand on previous 
research [11] and report on the findings of a quali-
tative investigation into the factors that influence 
mothers’ decision to enroll their HIV-negative 
infants in a hypothetical HIV vaccine trial.
Method
●● Participants
Participants were HIV-positive and HIV-nega-
tive women enrolled at the Maternal Obstetric 
Unit (MOU) at Site B in Khayelitsha, a large 
peri-urban township in South Africa. The 
MOU is the largest of two public sector deliv-
ery units located within Khayelitsha, with more 
than 200 new clients booking appointments for 
antenatal care per week [18]. On average, Site B 
MOU provides antenatal care to approximately 
350 patients per month [19] and recent estimates 
suggest that 30–32% of deliveries at this facil-
ity are to HIV-infected mothers [Rosenthal KL, 
Unpublished data]. To be included in the study, 
women had to be aged 18 years or older and 
be the mother of an HIV-negative infant. 
Women were excluded from the study if they 
had received a diagnosis of psychotic illness or 
developmental delay. Data were collected at two 
time points – October 2012 to January 2013 and 
October 2015 to March 2016. Mothers were only 
 interviewed once at a single time point.
Purposive sampling was used to select par-
ticipants [20]. MOU staff members informed 
enrolled mothers of the study, and those who 
expressed an interest in taking part were invited 
to provide their contact details to the research 
team. Data collectors contacted all prospective 
participants and arranged a meeting to discuss 
the study in further detail. All participants were 
informed that they would continue to receive 
services offered at the MOU, regardless of 
whether or not they chose to participate in the 
study.
All participants were given an information 
sheet that they discussed with a bilingual 
data collector (in their preferred language, see 
 supplementary Material). Consent forms were read 
aloud to all participants, and participants were 
asked at regular intervals whether they had any 
questions. Participants were then asked to sum-
marize the study in their own words and explain 
the rationale for their future participation. At 
this point, any misunderstandings relating to 
the study procedures or the potential benefits or 
risks of the project were addressed. Participants 
were then asked to sign an informed consent 
form, a copy of which was retained by partici-
pants along with contact information for the 
research team. All participants were informed 
that they could withdraw from the study at any 
time. Participants were given a R80 (US$5.66) 
shopping voucher as a token of appreciation for 
their participation in the study.
●● assessments
Semistructured, face-to-face qualitative inter-
views were conducted by bilingual data collectors 
in Xhosa (the primary local language) or English 
as per participant preference at a research center 
in Khayelitsha (see  supplementary Material). 
All interviews were audio recorded (with par-
ticipant permission) in full to ensure  reliability. 
 Interviews took place across two time points.
The interview guide was developed based 
on the research questions and the literature on 
parental attitudes toward enrollment of children 
in clinical trials. The interview guide was first 
piloted on several participants and interview 
questions were then refined based on partici-
pant responses. Interview questions focused on 
maternal understanding of HIV, experiences of 
vaccinations and perceptions of HIV vaccine 
clinical trials. Mothers were also asked for their 
views on whether they would enroll their child in 
an HIV vaccine trial and the factors that would 
influence their decision. All participants were 
informed that this research pertained to a hypo-
thetical vaccine trial and that there are risks and 
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benefits to every vaccine. In line with qualita-
tive research methods, data collection continued 
until  saturation was reached.
Interviews were first translated and tran-
scribed by an independent, bilingual tran-
scriber who did not conduct the interview. The 
transcripts were reviewed by the data collector 
who conducted the interview for accuracy. Any 
disagreements in the translation of the tran-
scripts were discussed between the researches 
and resolved following a re-examination of the 
interview audio recording.
●● Data analysis
To facilitate the organization and analysis 
of the data, transcripts were imported into 
NVivo 10 [21] and coded using thematic ana-
lysis [22]. Authors used the steps proposed by 
Braun & Clarke: repeated re-reading of the 
data, developing initial codes, searching for 
and generating candidate themes, and revis-
ing, defining and organizing themes. Themes 
were abstracted from the codes [23] with themes 
representative of repeated patterns of meaning 
across the dataset [22]. Authors V Williamson 
and B Coetzee coded all transcripts indepen-
dently, with meetings held at regular intervals to 
discuss progress and agreement of codes as well 
as emerging themes. The credibility and trust-
worthiness of the findings were also ensured by 
peer debriefing [24]. Peer debriefing took place 
with feedback regarding the interpretation of the 
data from authors MT and AK, who have experi-
ence with maternal and child health research and 
qualitative methods.
●● ethics
The study was reviewed and approved by the 
Stellenbosch University Health Research Ethics 
Committee (S12/04/092).
Results
●● sample characteristics
A total of 22 women (12 HIV-infected and 
ten uninfected) participated in the interviews. 
The average age of the mothers was 32.4 years 
(range: 23–41 years), and the average age of 
their child was 4.5 years (range: 0–6 years). Of 
the 12 women who reported being HIV infected, 
only five reported that they were using ART at 
the time of the interview. Half of the partici-
pants (11 out of 22) were married and on average 
had two biological children and three household 
members.
●● Results from thematic analysis
As delineated in Box 1, three overarching themes 
with accompanying subthemes were identified 
following thematic analysis of the data.
●● Perceptions of hiV 
Understanding & acceptance of HIV diagnosis
Both HIV positive and negative mothers per-
ceived HIV to be an incurable but controllable 
illness. Many of the HIV-positive mothers in 
this study learnt about their status during preg-
nancy. Mothers stated that they understood and 
accepted their diagnosis, accepted the impor-
tance of adherence to ART and believed that 
individuals living with HIV were able to enjoy 
long and productive lives on ART. As such, 
mothers perceived HIV to no longer be a death 
sentence. Mothers’ understanding of HIV and 
the subsequent acceptance of its manageability 
through ART was largely attributable to infor-
mation received from nurses and counselors at 
the clinic. One participant stated:
“If you are diagnosed with HIV, it is not the 
end of the world. Because you are not sick or 
feel any pain. You are able to go and work for 
your children. You can’t say just because you 
have got HIV, it is the end of the world… You 
can go anywhere as long as you treat it” (Fezeka, 
27 years, HIV uninfected).
Understanding of HIV infection
Mothers stated that they could protect them-
selves from being infected with HIV by using 
condoms and wearing gloves when exposed to 
an infected person’s blood or assisting a person 
with HIV. While most mothers perceived HIV 
to be contacted through sexual intercourse and 
contact with infected blood, some still held inac-
curate beliefs about how HIV is contacted. For 
example, one mother stated.
“According to my knowledge, HIV is the 
virus inside human body in the blood. And when 
you have many diseases inside your body, they 
combine and make HIV” (Khethiwe, 47 years, 
HIV infected).
●● Understanding of vaccines 
Knowledge of vaccines
Mothers’ knowledge and understanding of vac-
cinations generally were often limited. Primarily, 
mothers’ knowledge of vaccines were restricted 
to their experiences of vaccinating their own 
child. Mothers often reported that they did not 
know what disease their child was being vacci-
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nated against and simply accepted vaccination 
of their children as per the basic instructions of 
medical staff (i.e. that they should bring their 
child to the clinic on a certain date for their 
immunizations).
Vaccines as protective
Mothers stated that they believed that vaccines 
served a protective function. Specifically, moth-
ers reported that if their child received the neces-
sary vaccinations, he or she would not experience 
illnesses or physical disabilities unlike children 
who had not been vaccinated. One mother 
stated:
“I think vaccines are made for the child to be 
right, I mean for the child to have a normal life. 
When they say maybe there will be a diseases 
coming, children usually go for the vaccine. for 
the child to be safe. When we grow up we would 
see children who are disable and wonder what 
happened, only to find out that they were not 
vaccinated when they were infants” (Mandisa, 
33 years, HIV uninfected).
As such, vaccinations were considered vital 
to a child’s well-being and an act of maternal 
responsibility and caring. Neighboring children 
in the community who had not been vaccinated 
were often thought to have been irresponsible, 
unfit parents. This belief regarding the impor-
tance of vaccines is illustrated in the following 
excerpt:
“We grew up seeing this baby who is disa-
bled, but we thought the baby was like that from 
birth. It’s only my mother that told us that was 
the cause of not taking the baby for vaccine, 
because the (child’s) mother was busy drinking 
and careless about taking the child to the clinic 
for vaccine and the child ended up disabled” 
(Mandisa, 33 years, HIV uninfected).
Further, respondents stated that often chil-
dren in the community were not vaccinated 
because their parents were unwilling to wait 
for long periods at medical clinics. Similarly, 
respondents reported that children whose par-
ents were substance abusers were less likely to 
vaccinate their children.
Knowledge of HIV vaccines & vaccine trials
Mothers were unaware that a vaccine was being 
developed for HIV. Mothers often had limited 
knowledge of the purpose and procedures of a 
vaccine clinical trial, with many unable to com-
ment as to how a trial would be undertaken. 
However, in some cases, mothers’ understand-
ing of the hypothetical HIV vaccine trial was 
informed by their knowledge of ARV clinical 
trials. In these cases, mothers understood that 
ARVs were tested on individuals for effectiveness 
and potential side effects prior to their wider dis-
tribution, and the HIV vaccine trial was thought 
to follow the same process.
Interviewer: “Now let’s say the trials are about 
to start, would you bring your child?”
Mother: “Yes I would bring my child… I 
would bring her regardless. Even the ARVs 
were tested before being administered to people” 
(Fezeka, 27 years, HIV uninfected).
●● Factors influencing decision to vaccinate 
Willingness to participate
For the most part, mothers stated that they were 
willing and interested in their children partici-
pating in an HIV vaccine trial and that there was 
very little that would stop them from doing so. 
Mothers stated that their willingness to enroll 
their child in the trial would be increased after 
seeing other children successfully vaccinated 
against HIV. As stated by one mother:
“If it’s tested and proven that it is safe and 
working and the vaccinations are being con-
ducted on other children, I must also take my 
baby” (Buhle, 31 years, HIV infected).
Even so, there were some who were concerned 
about confidentiality during participation. 
Another mother stated:
“Then, the one who told herself that I’m going 
to take my child to that place and found out that 
Box 1. themes and subthemes following 
thematic analysis.
Perceptions of hiV
 ● Understanding of HIV
 ● Understanding of HIV infection
 ● Acceptance of diagnosis
Understanding of vaccines
 ● Knowledge of vaccines
 ● Vaccines as protective
 ● Knowledge of HIV vaccines and vaccine trials
Factors influencing decision to vaccinate
 ● Willingness to participate/interest in taking 
part
 ● Social influences
 ● Ultimately maternal decision
 ● Protectiveness (factor in altruism)
 ● Concerns of HIV vaccine side effects
 ● Distrust in vaccination trials
 ● Trust in medical staff
 ● Ease of access to vaccine
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her child has that thing, then comes back and 
tell her neighbour that girl I went to that place 
and I found out that my child has that thing” 
(Mandisa, 33 years, HIV uninfected).
Here, stigma and the possibility of being seen 
by others at a clinic acted as a potential barrier 
to participation. Mothers also stated that others 
within the community would be willing to vac-
cinate their children as it would mean not having 
to go to the clinic, where extensive waiting times 
existed, for regular HIV testing.
Social influences
Mothers stated that they would for the most 
part consult their child’s father on whether or 
not to enroll their child in the vaccine trial. For 
many, consulting their child’s father was con-
sidered necessary as important decisions regard-
ing their children were often made together as 
a couple. Mothers also stated that, in addition 
to their child’s father, they would consult other 
members of their household and family with a 
view to receiving support for their decision to 
vaccinate the child. As one mother stated:
“I think getting a support might help me. I 
don’t want when I get home and discuss this and 
get a negative response. Support would help me 
a lot… It should come from our household. I 
don’t want to be alone in this, as if it’s my idea” 
(Fezeka, 27 years, HIV uninfected).
Individuals (e.g., fathers, household mem-
bers, family) chosen by mothers as possible 
consultants in such a decision were considered 
to be understanding, trustworthy and capable of 
 providing support.
Ultimately maternal decision
While mothers stated that they would consult 
others regarding trial participation, the final 
decision as to whether or not their child would 
participate reportedly rested with the mother. As 
stated by one mother:
“When you make decisions like this, it’s 
important to tell someone, that there is this 
thing and I would like to do it. That is impor-
tant, although the decision is ultimately yours to 
take. But it’s good to get other people’s opinions 
as well” (Khanyiswa, 23 years, HIV uninfected).
Protectiveness (factor in altruism)
Mothers often believed that an HIV vaccine trial 
would be effective in preventing their child from 
contacting HIV. Mothers expressed a strong 
desire for their child to not contact the HIV 
virus and took several steps to prevent their child 
from contacting HIV in utero and immediately 
following their birth. In line with this, the HIV 
vaccine trial represented a means for mothers to 
safeguard their child’s health and ensure they 
did not contact HIV later in life. As children 
were considered particularly vulnerable to con-
tacting HIV, either while playing with other 
children and accidentally coming into contact 
with another child’s blood, or from later sexual 
intercourse as adults, participants stated that the 
vaccine offered reassurance and peace of mind 
for mothers that their child would remain HIV 
negative.
Mothers often perceived considerable stigma 
of HIV in their community and reported con-
cerns that, should their child be HIV positive, 
they would be stigmatized by other children or 
ask their parents difficult questions about how 
they contacted the virus, neither of which the 
mother felt able to address. As a result, their 
child’s participation in the trial represented a 
means of protection, not only from the virus but 
from the associated stigma as well. As stated by 
one mother:
“Because at my house I am the only one who 
is infected. All I’m saying (is that) I wouldn’t 
love to have a child with HIV because it’s not 
nice to take treatment with your child. The child 
will grow with anger saying that ‘Mama, other 
children are laughing at me. Why me’? You end 
up facing serious questions that you can’t answer. 
‘Why did I get infected’? Those are difficult 
 questions” (Fezeka, 27 years, HIV uninfected).
Mothers also reported that their child’s par-
ticipation in the hypothetical HIV vaccine trial 
could potentially result in wider community 
benefits. Children’s participation in the trial 
was thought to have the potential to lead to the 
reduction in the number of individuals with 
HIV. In these cases, mothers were particularly 
willing to enroll their child in the hypothetical 
vaccine trial. As stated by one mother:
Interviewer: “…Can you give me some reasons 
why you would let (your) baby take part?”
Mother: “I would let him take part so that 
we can see what will help children… and so 
that there could be a decrease on these diseases” 
(Babalwa, 32 years, HIV infected).
Concerns of HIV vaccine side effects
Attitudes toward the HIV vaccine trial were 
not all positive. A number of mothers reported 
concerns regarding the potential side effects of 
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the HIV vaccine trial. Mothers were concerned 
that their child could become sick, develop a 
rash or allergies which they did not have prior 
to the trial, or even die. In such cases, mothers 
did not want their child to take part in the trial, 
instead preferring for their child to participate 
once the vaccine had been proven safe. More-
over, mothers feared that if they took their child 
to be vaccinated against HIV, he or she would 
become infected with the virus. Given mothers’ 
anxiety and distrust in clinical trials in these 
cases, the provision of information regarding the 
safety and efficacy of the vaccine was considered 
important. As stated by one mother:
Mother: “I mean people talk, like I would 
let my child to take part on these vaccines to 
be tested on him but some people will say no, 
white people are making money by using your 
children… your children will die and white 
people will make your children sick, things like 
that. People always talk bad things, you know, 
and those things will make me wonder” (Buhle, 
31 years, HIV infected).
Other participants felt that members of the 
community would believe that receiving an HIV 
vaccination meant that the child was HIV posi-
tive. Nonetheless, as previously mentioned, moth-
ers were often willing for their child to take part in 
the trial, despite the potential risk of side effects, 
as being vaccinated against HIV was thought to 
outweigh the risk of possible  vaccine side effects.
Trust in medical staff
Mothers often desired the opportunity to discuss 
and receive guidance about the trial from medi-
cal staff or social workers. Mothers reported hav-
ing additional questions about how the vaccine 
would work, who would be eligible to participate, 
and queries about potential side effects. Medical 
staff, including doctors and nurses, were largely 
seen as trustworthy, reliable sources of advice 
and mothers felt that they could approach medi-
cal staff for this support regarding the decision 
to enroll their child. As stated by one mother:
Mother: “I think I would go to a nurse or social 
worker. They know better than me. They can give 
me the best advice when it comes to health and 
can also tell me about the risks that are involved 
in the process. And how important is this to my 
child” (Khuthala, 33 years, HIV uninfected).
Ease of access to vaccine
Mothers were particularly knowledgeable about 
potential ways that healthcare workers could 
increase trial participation in the community. 
Mothers stated that it was common for health-
care staff to drive around in the communities 
and promote vaccinations over a loudspeaker. 
The vaccinations would then be administered 
to children on site, and families could avoid the 
considerable waiting times experienced at clin-
ics. Having vaccinations accessible at commu-
nity level was deemed by mothers to be a neces-
sary condition if HIV vaccinations were not a 
one-off treatment and needed to be administered 
routinely each year. As stated by one mother:
“Like with the polio ones, so vaccines are done 
in the same way, maybe they won’t do it just 
once, (…) maybe they will say they must come 
again when they turn seven and maybe again at 
the age of 14, vaccines work like that” (Babalwa, 
32 years, HIV infected).
Discussion
The aim of this study was to explore the factors 
influencing maternal willingness to enroll their 
HIV-negative infants in a hypothetical HIV vac-
cine trial. The narratives uncovered key themes 
relating to: maternal understandings of HIV; 
attitudes toward vaccination more generally; 
and the social, cultural and situational factors 
determining mother’s decisions to enroll their 
child in the trial.
Our findings show that despite a fairly good 
knowledge of HIV, ART and vaccines in general, 
mothers tended to have little or no knowledge 
of HIV vaccines and HIV vaccine trials. Studies 
have shown that poor knowledge of HIV vac-
cines and trial methodology is associated with 
reduced willingness to participate [25], and this 
finding may represent a potential barrier to the 
enrollment of children in future vaccine trials. 
Of concern, vaccinations that mothers appeared 
to be more familiar with (e.g. polio), were report-
edly often administered with limited communi-
cation between the parent and health worker. 
Instead, such vaccines were administered as an 
apparently routine act that required little mutual 
negotiation. The results of this study highlight 
the need for healthcare workers in future vaccine 
trials to ensure that parents are provided with 
accurate and sufficient information to maintain 
motivation to comply with and complete the 
trial.
Despite relatively poor maternal understand-
ing of HIV vaccines and how they work, the 
majority of mothers were interested in enrolling 
their child in a trial, mainly because of anxiety 
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that their child could develop HIV in the future. 
The vaccine trial represented a means of reassur-
ance that their child would be protected from 
contacting the virus. In such cases, the poten-
tial side effects and inherent risks of participa-
tion in the trial were reportedly outweighed by 
the possible benefits of participating. Notably, 
mothers believed that the vaccine would be 
protective despite receiving information from 
the study researchers that the effectiveness of 
the hypothetical vaccine trial had not been 
proven. This finding is in keeping with those of 
Otowombe et al. that adolescents were willing 
to participate in HIV research despite having 
knowledge of negative trial results [26].
Contributing to mothers’ decisions to enroll 
in a trial were also beliefs that they could 
approach and trust medical staff for guidance 
about the trial as well as ease of access to the 
vaccination procedure. These results highlight 
the need for healthcare workers to be mindful 
of their position of trust and authority when 
providing information regarding vaccine trials. 
In particular, as mothers believed that the hypo-
thetical vaccine would provide their child with 
lifelong protection against HIV, this may have 
implications for future trials. Thus healthcare 
providers should be aware of parental expecta-
tions and provide guidance regarding the poten-
tial need for booster vaccinations. Moreover, the 
findings indicate that healthcare workers must 
deliver information regarding the potential risks 
and benefits to child participation in a vaccine 
trial in a balanced fashion and ensure that par-
ents fully understand the possible side effects of 
a trial before providing consent.
Mothers also reported several social harms 
associated with trial participation. Some moth-
ers feared that others would assume that par-
ticipation in the trial meant that their children 
were infected and that they would, therefore, 
be discriminated against. These results are in 
keeping with previous research that has found 
mistrust in vaccine trials to be an inhibitor of 
WTP [27–31]. A common misperception persists 
that HIV trial participants are in fact infected 
with HIV or at high risk of infection [32], which 
is in part due to the presence of HIV antibod-
ies, a normal immunological response, after 
receiving the candidate vaccine [33]. Therefore, 
the guidance provided to parents who are con-
sidering enrolling their child in an HIV vac-
cine trial may be enhanced by the inclusion of 
information that would address these concerns. 
Furthermore, these findings may also have 
implications for the Phase III trials (HVTN 
702) that are expected to commence in South 
Africa in November 2016 (pending regulatory 
approval) amongst HIV-uninfected adults. 
Adults may avoid participating in HIV vaccine 
trials due to similar concerns, such as fear of 
discrimination or stigma from family members 
or the community. Education about vaccine tri-
als delivered at a community level may serve to 
improve the acceptability of and willingness to 
participate in HIV vaccine trials by diminishing 
stigma and future research is needed to evaluate 
this response.
Mothers associated vaccinations with mater-
nal qualities of care and responsibility and fail-
ure to vaccinate was considered to be irrespon-
sible and indicative of parental laziness. This 
finding may have implications for future inter-
ventions that aim to improve uptake of routine 
vaccinations for young children. As such, future 
interventions may benefit from placing mobile 
vaccination units in the community or conduct-
ing home-based vaccinations within households. 
In this way, children whose parents/caregivers 
do not take them for vaccinations (for various 
reasons including parental laziness) will also be 
reached.
This study had several strengths and weak-
nesses. Among the strengths is the recruitment 
of both HIV-positive and negative mothers 
which allowed for the collection of a wide 
range of maternal views. However, a weakness 
of this study was the exclusive recruitment of 
mothers. As children often receive care from a 
number of other relatives in this context [34–37], 
the collection of views from other caregivers, 
such as grandmothers, and fathers would allow 
for a better understanding of the factors influ-
encing caregivers’ decision to enroll children 
in an HIV vaccine trial. Further, it was not 
possible to conduct member checking and pro-
vide participants with a copy of the interview 
transcripts and preliminary findings which 
must be acknowledged as a limitation. Given 
the nature of qualitative research which aims 
to explore participants experiences [22,38] these 
findings may not generalize to other samples; 
however, these results are in keeping with pre-
vious qualitative HIV trial research conducted 
in adolescent and adult populations. Moreover, 
it is possible that maternal responses in the pre-
sent study may have been influenced by social 
desirability bias given the sensitive nature of 
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the interview topic. Finally, while women in 
this study indicated that they would be will-
ing to enroll their HIV-negative infants into 
a hypothetical HIV trial, we do acknowledge 
that this willingness may not translate to actual 
willingness in a real trial. These limitations 
executive summary
Background
 ●  There is some evidence on adolescents and adults’ willingness to participate in HIV vaccine trials. However, very little is 
known about the willingness of parents to enroll their children in HIV vaccine trials and the factors that influence such 
a decision.
 ●  The aim of the present study was to explore the factors influencing mothers’ decision to enroll their HIV-negative 
infants in a hypothetical HIV vaccine trial.
Methods
 ●  A total of 22 women (12 HIV-infected and ten uninfected) from the Maternal Obstetric Unit at Site B in Khayelitsha 
participated in the interviews.
 ●  Interviews were audio-recorded and transcribed verbatim. Transcripts were analyzed using thematic analysis in NVivo 10.
Results
 ●  We identified three overarching themes: perceptions of HIV; understanding of vaccines; and factor influencing decision 
to vaccinate.
 ●  Our findings showed that while women in this study had knowledge of HIV, ART and vaccines in general, mothers 
tended to have little or no knowledge of HIV vaccines and HIV vaccine trials.
 ●  Our findings also showed that while mothers were familiar with vaccinations more generally, these were often 
administered with limited communication from healthcare providers as to the vaccines purpose and functioning.
 ●  Mothers were for the most part eager to enroll their negative infants into vaccine trial research, as they considered this 
a valuable form of protection from future HIV infection.
 ●  Some mothers reported concerns regarding the stigma associated with participation in HIV vaccine research.
 ●  Also contributing to mothers’ decisions to enroll in the hypothetical trial were beliefs that they could approach and 
trust medical staff for guidance about the trial as well as ease of access to the vaccination.
 ●  Some mothers associated child vaccinations with maternal care and responsibility, while failure to vaccinate was 
considered to be irresponsible and indicative of parental apathy.
Discussion
 ●  HIV vaccine trial participants require knowledge on the risks and benefits associated with vaccine research, as 
poor knowledge of HIV vaccines and trial methodology is associated with reduced willingness to participate. Such 
information could be provided by healthcare workers in future vaccine trials and is necessary in order to maintain 
motivation to comply with and complete the trials.
 ●  The potential protectiveness of the HIV vaccine against the virus was a salient issue in this study. However, in the 
context of an experimental vaccine trial, research participants may need reminding of the risks and benefits associated 
with participation.
 ●  Several inhibitors to participation, including mistrust of vaccine trials, were identified as important barriers to 
participation in this study which is consistent with previous research. The presence of HIV antibodies following HIV 
vaccination has been interpreted as deliberate infection. These results indicate that the provision of information to 
participants in HIV vaccine trial research that would address these concerns may be beneficial.
 ●  At a community level, more information about HIV vaccine trials may improve the acceptability of trials and reduce the 
stigma associated with trial participation.
 ●  This study identified several social, psychological, environmental and behavioral factors that influence HIV vaccine 
trial participation. In order to ensure that future HIV vaccine trials are conducted in a respectful and ethically sound 
manner, more research is needed to fully explore and understand barriers to participation.
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notwithstanding, this study provides a novel 
exploration of the factors influencing mother’s 
decisions on whether to enroll their child in an 
HIV vaccine trial.
conclusion
In the context of vaccine trial acceptability and 
willingness to participate, the results of this 
research illustrate the concerns held by mothers 
and potential barriers to child participation in 
future vaccine trials. Our findings may be use-
ful to vaccine trial investigators who are tasked 
with providing information to parents who are 
considering enrolling their child in future HIV 
vaccine trials. Our findings also suggest the need 
for healthcare providers to sensitively deliver 
trial information to parents. Taken together, 
this study highlights the social, psychological, 
environmental and behavioral factors influenc-
ing vaccine trial participation that are important 
to understand if we are to facilitate willingness 
to participate in several thousands of eligible 
participants in future trials that are respectful 
and ethically sound.
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